Young Chan Kim

Clinical Non-Stipendiary Lecturer; Sir Henry Wellcome Fellow; Principal Investigator; Junior Research Fellow (Wolfson); NHS Doctor

I am Sir Henry Wellcome Fellow, Principal Investigator (PI), Junior Research Fellow (JRF) at Wolfson College, and NHS doctor.

I completed a BSc degree in Biochemistry from Imperial College London and my medical degrees (BMBS, BMedSci and MRes) from the University of Nottingham. I then spent few years working in junior doctor posts before coming to Oxford to start a DPhil in Clinical Medicine. My DPhil studies focused on vaccine development against arthropod-borne viruses supported by Innovate UK funding. I was awarded highly prestigious NDM Graduate Student Prize 2020 (Overall Prize Winner) for my overall performance during my DPhil at the Nuffield Department of Medicine (NDM) and a NIHR Oxford BRC Grant to support my research as a Postdoctoral Fellow. In 2022, I was awarded the Sir Henry Wellcome Fellowship to start my independent research on vaccine development against emerging arboviruses. In 2022-2023, I have been awarded MRC HIC-VAC and MRC IAA grants to develop serological assays against typhoid and paratyphoid fever and the MLSTF grant to develop a vaccine against Chagas disease.

I am currently a Sir Henry Wellcome Fellow, a Principal Investigator (PI) at the Oxford Vaccine Group (OVG), a JRF Fellow at Wolfson College, a Lecturer in Medicine at Somerville College, and a doctor in Acute Internal Medicine in the Oxford University Hospitals NHS Foundation Trust.


  • López-Camacho C & Kim YC, et al. (2019). Assessment of Immunogenicity and Neutralisation Efficacy of Viral-Vectored Vaccines Against Chikungunya Virus. Viruses, 11 (4).

  • Kim YC, et al (2020). COVID-19 Vaccines: Breaking Record Times to First-in-Human Trials. NPJ Vaccines, 5, 34.

  • Kim YC, et al (2020). Evaluation of Chimpanzee Adenovirus and MVA Expressing TRAP and CSP from Plasmodium Cynomolgi to Prevent Malaria Relapse in Nonhuman Primates. Vaccines (Basel), 8 (3).

  • Folegatti P, et al (2021). A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial. Nat Commun. 12, 4636 2021.

  • Kim YC, et al (2022). Development of novel viral vectored vaccines and virus replicon particle-based neutralization assay against Mayaro virus. Int. J. Mol. Sci. 2022, 23, 4105.

Where Next?